Evidence method
Level · gp.fundamentals.capex_revenue_ratio
310.57% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CRNX · Jun 30, 2025
Crinetics Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-25-175498General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-8326.96% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
158.40% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-12522.99% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
7788.65% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
2533.85% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History14 statesSelf-history eligible
Sep 30, 20190/6 normalizedLevel 3Dec 31, 20190/6 normalizedLevel 3Mar 31, 20200/6 normalizedLevel 3Dec 31, 20200/6 normalizedLevel 3Mar 31, 20235/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Dec 31, 20256/8 normalizedLevel 3Mar 31, 20266/8 normalizedLevel 3Jun 30, 20266/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 343.21%
- Current
- 310.57%
- Delta
- -32.64%
- Previous
- -24501.94%
- Current
- -8326.96%
- Delta
- 16174.98%
- Previous
- -43.59%
- Current
- 158.40%
- Delta
- 201.99%
- Previous
- -30860.11%
- Current
- -12522.99%
- Delta
- 18337.12%
- Previous
- 21119.11%
- Current
- 7788.65%
- Delta
- -13330.46%
- Previous
- 5672.58%
- Current
- 2533.85%
- Delta
- -3138.73%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Analogous To · CRNX state analogue 3 →Transitioned To · CRNX Fundamental State →Transitioned To · CRNX CAPEX_INTENSITY_DECREASED →Transitioned To · CRNX CASH_GENERATION_INCREASED →Transitioned To · CRNX GROWTH_INCREASED →Transitioned To · CRNX PROFITABILITY_INCREASED →Transitioned To · CRNX R_AND_D_INTENSITY_DECREASED →Transitioned To · CRNX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.